GYRE THERAPEUTICS, INC.
GYRENasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $116.6M | $105.8M | $113.5M | $102.3M | $7.3M | $20.9M |
| Operating income | $11.5M | $16.2M | −$67.2M | −$8.6M | −$87.9M | −$57.4M |
| Net income | $9.9M | $17.9M | −$85.5M | −$8.2M | −$87.9M | −$56.2M |
| Total assets | $166.1M | $125.4M | $116.5M | $28.4M | $55.7M | $94.8M |
| Total liabilities | $23.9M | $27.0M | $38.1M | $16.8M | $14.6M | $18.8M |
| Equity | $106.0M | $63.3M | −$15.8M | −$21.7M | $41.1M | $76.1M |
| EPS (diluted) | $0.02 | $0.05 | $-1.41 | $-0.26 | $-2.87 | — |
| Shares out. | 93.6M | 85.4M | 37.8M | 31.5M | 31.3M | 12.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 9.9%
- Net margin
- 8.5%
- Return on equity
- 9.3%
- Return on assets
- 5.9%
- Return on capital (ROCE)
- 7.8%
- Liabilities / assets
- 14.4%
- Debt / equity
- 0.22×
- Book value / share
- $1.13
- Revenue growth (YoY)
- 10.2%
- Net income growth (YoY)
- −44.8%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 7.11safe
- Accruals / assets
- 5.3%moderate
- Beneish M-Score
- -1.76elevated
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 5 good- Beneish M-Score elevated — earnings-manipulation screen flag
- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Ma SongjiangActivist (13D)May 7, 2026
- Luo YingActivist (13D)May 6, 2026
- Gni Group Ltd.Activist (13D)May 6, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.7M | 18.2 | +6.0% |
| Apr 30, 2026 | 1.6M | 32.6 | -0.2% |
| Apr 15, 2026 | 1.6M | 25.9 | +3.8% |
| Mar 31, 2026 | 1.5M | 10.8 | +10.8% |
| Mar 13, 2026 | 1.4M | 8.4 | +2.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureMay 14, 2026
- Regulation FD disclosureMay 12, 2026
- Results of operationsMay 7, 2026
- Completed an acquisition or disposition · Unregistered equity sale · Modified shareholder rights · Director / officer change · Amended charter or bylaws · Regulation FD disclosureMay 4, 2026
- Other material eventMar 23, 2026
- Regulation FD disclosureMar 12, 2026
- Results of operationsMar 12, 2026
- Entered a material agreement · Unregistered equity sale · Director / officer change · Amended charter or bylaws · Regulation FD disclosureMar 2, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.